The 1‑year return of +36.1% versus the S&P's +12.4% is a standout, demonstrating that CTRI has generated more than three times the market's gain, which underscores strong compounding potential for long‑term investors.
The long‑term premium could erode if CTRI's growth slows; a 20% deceleration in earnings CAGR would likely cut the excess return by roughly half, bringing performance closer to the S&P's +4.5% benchmark and reducing its attractiveness as an alpha source.
The combination of >100% institutional ownership and a recent 0.66% decline in those positions creates a crowded short‑term holder base; a negative catalyst could trigger rapid margin calls, magnifying downside beyond the historical max drawdown of -30.7%.
The 9.4% YoY revenue surge stands out as a potential catalyst for near‑term earnings acceleration, but its significance hinges on whether the underlying drivers are repeatable; if the boost stems from sustainable contract renewals, it could signal a breakout from the stagnant 1.5% three‑year CAGR.
The sub‑1% net margin combined with a negative free‑cash‑flow conversion (-0.3% of revenue) quantifies the risk: a 2-percentage-point increase in operating expenses would push the company into outright loss territory, highlighting fragility in its profitability structure.
The sharp drop in operating margin to sub‑1% is the most concerning profitability signal, because it signals that even modest revenue growth cannot cover rising cost pressures, threatening sustainable return on equity.
| Year | ROE% | Margin% | Turnover | Leverage | ROIC% | ROCE% | ROA% |
|---|---|---|---|---|---|---|---|
| 2025 | 2.6 | 0.8 | 1.20 | 2.76 | 5.2 | 4.9 | 0.9 |
| 2024 | -1.2 | -0.3 | 1.27 | 3.73 | 5.5 | 5.1 | -0.3 |
| 2023 | -82.4 | -6.4 | 1.32 | 9.69 | -4.5 | -4.4 | -8.5 |
| 2022 | -43.5 | -6.1 | 1.12 | 6.34 | -5.1 | -5.0 | -6.9 |
| 2021 | 8.4 | 1.9 | 0.84 | 5.35 | 4.6 | 4.5 | 1.6 |
| 2020 | 3.3 | 0.0 |
The widening gap between ROIC (5.2%) and cost of capital (~7.5%) quantifies a risk of continued value erosion; if operating margin does not rebound above 1%, the company will persistently destroy shareholder wealth on each dollar deployed.
| Year | Total Asset Days | Inventory Days | Receivables Days | Fixed Asset Days | Payables Days | Cash Conversion Cycle |
|---|---|---|---|---|---|---|
| 2025 | 305 | 0 | 40 | 84 | 27 | 13 |
| 2024 | 287 | 0 | 72 | 90 | 19 | 53 |
| 2023 | 276 | 0 | 78 | 89 | 16 | 62 |
| 2022 | 324 | 0 | 84 | 91 | 21 | 63 |
| 2021 | 434 | 0 | 86 | 110 | 17 | 69 |
| 2020 | 0 | 0 | 0 | 0 |
| Year | Total Assets | Total Liabilities | Total Equity | Total Debt | Net Debt | Cash | Current Assets | Current Liabilities |
|---|---|---|---|---|---|---|---|---|
| 2025 | $2408M | $1529M | $873M | $321M | $195M | $127M | $881M | $496M |
| 2024 | $2074M | $1514M | $556M | $1009M | $960M | $49M | $601M | $382M |
| 2023 | $2190M | $1865M | $226M | $1311M | $1278M | $33M | $683M | $421M |
| 2022 | $2454M | $1910M | $387M | $1334M | $1270M | $64M | $733M | $426M |
| 2021 | $2568M | $1891M | $480M | $1362M | $1248M | $115M | $664M | $344M |
| 2020 |
| Year | Operating CF | Investing CF | Financing CF | CapEx | Free Cash Flow | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| 2025 | $78M | $-88M | $89M | $-86M | $-8M | ||
| 2024 | $158M | $-89M | $-53M | $-99M | $59M | ||
| 2023 | $167M | $-95M | $-103M | $-107M | $61M | ||
| 2022 | $95M | $-117M | $-27M | $-130M | $-35M | $-15M | |
| 2021 | $109M | $-917M | $884M | $-110M | $-1M | $-31M | |
| 2020 | $200M | $-125M | $-43M | $-133M | $67M | $-26M |
This report is generated by Finexus and is provided for informational purposes only. It does not constitute investment advice, a recommendation, or an offer or solicitation to buy or sell any security.
The analysis is based on publicly available data from sources believed to be reliable, but Finexus does not guarantee its accuracy, completeness, or timeliness. Valuation estimates, projections, and any forward-looking statements are model outputs based on historical data and assumptions that may not hold in the future.
Past performance is not indicative of future results. Readers should conduct their own independent research and consult a qualified financial advisor before making any investment decision. Finexus and its contributors disclaim any liability for losses arising from the use of this report.
Created 2026-06-07 · finexus.net